Filing Details
- Accession Number:
- 0001140361-21-030941
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-10 17:06:07
- Reporting Period:
- 2021-09-09
- Accepted Time:
- 2021-09-10 17:06:07
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1559053 | Prothena Corp Public Ltd Co | PRTA | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1692214 | D. Carol Karp | C/O Prothena Biosciences Inc 331 Oyster Point Boulevard South San Francisco CA 94080 | Chief Regulatory Officer | No | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Ordinary Shares, Par Value $0.01 Per Share | Acquisiton | 2021-09-09 | 10,000 | $15.04 | 10,000 | No | 4 | M | Direct | |
| Ordinary Shares, Par Value $0.01 Per Share | Disposition | 2021-09-09 | 5,458 | $71.45 | 4,542 | No | 4 | S | Direct | |
| Ordinary Shares, Par Value $0.01 Per Share | Disposition | 2021-09-09 | 4,542 | $72.63 | 0 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2021-09-09 | 10,000 | $0.00 | 10,000 | $15.04 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 140,000 | 2028-06-21 | No | 4 | M | Direct |
Footnotes
- The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- The transaction was executed in multiple trades in prices ranging from $70.94 to $71.75, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The transaction was executed in multiple trades in prices ranging from $72.16 to $72.83, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
Billionaire Hedge Funds
